Priyanka Garg1, Angelos Oikonomopoulos1, Haodong Chen1, Yingxin Li1, Chi Keung Lam1, Karim Sallam1, Marco Perez2, Robert L Lux3, Michael C Sanguinetti4, Joseph C Wu5. 1. Stanford Cardiovascular Institute and Department of Medicine, Division of Cardiology, Stanford University, Stanford, California. 2. Stanford Cardiovascular Institute and Department of Medicine, Division of Cardiology, Stanford University, Stanford, California; Center for Inherited Cardiovascular Disease, Division of Cardiovascular Medicine, Stanford University, Stanford, California. 3. Nora Eccles Harrison Cardiovascular Research and Training Institute, University of Utah, Salt Lake City, Utah. 4. Nora Eccles Harrison Cardiovascular Research and Training Institute, University of Utah, Salt Lake City, Utah; Division of Cardiovascular Medicine, Department of Internal Medicine, University of Utah, Salt Lake City, Utah. 5. Stanford Cardiovascular Institute and Department of Medicine, Division of Cardiology, Stanford University, Stanford, California. Electronic address: joewu@stanford.edu.
Abstract
BACKGROUND: The long QT syndrome (LQTS) is an arrhythmogenic disorder of QT interval prolongation that predisposes patients to life-threatening ventricular arrhythmias such as Torsades de pointes and sudden cardiac death. Clinical genetic testing has emerged as the standard of care to identify genetic variants in patients suspected of having LQTS. However, these results are often confounded by the discovery of variants of uncertain significance (VUS), for which there is insufficient evidence of pathogenicity. OBJECTIVES: The purpose of this study was to demonstrate that genome editing of patient-specific induced pluripotent stem cells (iPSCs) can be a valuable approach to delineate the pathogenicity of VUS in cardiac channelopathy. METHODS: Peripheral blood mononuclear cells were isolated from a carrier with a novel missense variant (T983I) in the KCNH2 (LQT2) gene and an unrelated healthy control subject. iPSCs were generated using an integration-free Sendai virus and differentiated to iPSC-derived cardiomyocytes (CMs). RESULTS: Whole-cell patch clamp recordings revealed significant prolongation of the action potential duration (APD) and reduced rapidly activating delayed rectifier K+ current (IKr) density in VUS iPSC-CMs compared with healthy control iPSC-CMs. ICA-105574, a potent IKr activator, enhanced IKr magnitude and restored normal action potential duration in VUS iPSC-CMs. Notably, VUS iPSC-CMs exhibited greater propensity to proarrhythmia than healthy control cells in response to high-risk torsadogenic drugs (dofetilide, ibutilide, and azimilide), suggesting a compromised repolarization reserve. Finally, the selective correction of the causal variant in iPSC-CMs using CRISPR/Cas9 gene editing (isogenic control) normalized the aberrant cellular phenotype, whereas the introduction of the homozygous variant in healthy control cells recapitulated hallmark features of the LQTS disorder. CONCLUSIONS: The results suggest that the KCNH2T983I VUS may be classified as potentially pathogenic.
BACKGROUND: The long QT syndrome (LQTS) is an arrhythmogenic disorder of QT interval prolongation that predisposes patients to life-threatening ventricular arrhythmias such as Torsades de pointes and sudden cardiac death. Clinical genetic testing has emerged as the standard of care to identify genetic variants in patients suspected of having LQTS. However, these results are often confounded by the discovery of variants of uncertain significance (VUS), for which there is insufficient evidence of pathogenicity. OBJECTIVES: The purpose of this study was to demonstrate that genome editing of patient-specific induced pluripotent stem cells (iPSCs) can be a valuable approach to delineate the pathogenicity of VUS in cardiac channelopathy. METHODS: Peripheral blood mononuclear cells were isolated from a carrier with a novel missense variant (T983I) in the KCNH2 (LQT2) gene and an unrelated healthy control subject. iPSCs were generated using an integration-free Sendai virus and differentiated to iPSC-derived cardiomyocytes (CMs). RESULTS: Whole-cell patch clamp recordings revealed significant prolongation of the action potential duration (APD) and reduced rapidly activating delayed rectifier K+ current (IKr) density in VUS iPSC-CMs compared with healthy control iPSC-CMs. ICA-105574, a potent IKr activator, enhanced IKr magnitude and restored normal action potential duration in VUS iPSC-CMs. Notably, VUS iPSC-CMs exhibited greater propensity to proarrhythmia than healthy control cells in response to high-risk torsadogenic drugs (dofetilide, ibutilide, and azimilide), suggesting a compromised repolarization reserve. Finally, the selective correction of the causal variant in iPSC-CMs using CRISPR/Cas9 gene editing (isogenic control) normalized the aberrant cellular phenotype, whereas the introduction of the homozygous variant in healthy control cells recapitulated hallmark features of the LQTS disorder. CONCLUSIONS: The results suggest that the KCNH2T983IVUS may be classified as potentially pathogenic.
Authors: Jamie D Kapplinger; David J Tester; Benjamin A Salisbury; Janet L Carr; Carole Harris-Kerr; Guido D Pollevick; Arthur A M Wilde; Michael J Ackerman Journal: Heart Rhythm Date: 2009-06-23 Impact factor: 6.343
Authors: Annukka Marjamaa; Veikko Salomaa; Christopher Newton-Cheh; Kimmo Porthan; Antti Reunanen; Hannu Karanko; Antti Jula; Päivi Lahermo; Heikki Väänänen; Lauri Toivonen; Heikki Swan; Matti Viitasalo; Markku S Nieminen; Leena Peltonen; Lasse Oikarinen; Aarno Palotie; Kimmo Kontula Journal: Ann Med Date: 2009 Impact factor: 4.709
Authors: Elena Matsa; James E Dixon; Christopher Medway; Orestis Georgiou; Minal J Patel; Kevin Morgan; Paul J Kemp; Andrew Staniforth; Ian Mellor; Chris Denning Journal: Eur Heart J Date: 2013-03-06 Impact factor: 29.983
Authors: Timon Seeger; Rajani Shrestha; Chi Keung Lam; Caressa Chen; Wesley L McKeithan; Edward Lau; Alexa Wnorowski; George McMullen; Matthew Greenhaw; Jaecheol Lee; Angelos Oikonomopoulos; Soah Lee; Huaxiao Yang; Mark Mercola; Matthew Wheeler; Euan A Ashley; Fan Yang; Ioannis Karakikes; Joseph C Wu Journal: Circulation Date: 2019-02-05 Impact factor: 29.690
Authors: Li Pang; Philip Sager; Xi Yang; Hong Shi; Frederick Sannajust; Mathew Brock; Joseph C Wu; Najah Abi-Gerges; Beverly Lyn-Cook; Brian R Berridge; Norman Stockbridge Journal: Circ Res Date: 2019-10-10 Impact factor: 17.367
Authors: Priyanka Garg; Vivek Garg; Rajani Shrestha; Michael C Sanguinetti; Timothy J Kamp; Joseph C Wu Journal: Circ Res Date: 2018-07-06 Impact factor: 17.367
Authors: Nikhil V Chavali; Dmytro O Kryshtal; Shan S Parikh; Lili Wang; Andrew M Glazer; Daniel J Blackwell; Brett M Kroncke; Moore Benjamin Shoemaker; Bjorn C Knollmann Journal: Heart Rhythm Date: 2019-04-18 Impact factor: 6.343
Authors: Gary Gintant; Paul Burridge; Lior Gepstein; Sian Harding; Todd Herron; Charles Hong; José Jalife; Joseph C Wu Journal: Circ Res Date: 2019-09-19 Impact factor: 17.367